Five Late-Breaking Studies To Look Out For At ASCO
Executive Summary
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.
You may also be interested in...
Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance
Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.
China Takes A Bigger Role In The World Pharma Stage
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
Five Late-Breaking Studies To Look Out For At ASCO
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.